High expression of UBE2T predicts poor prognosis and survival in multiple myeloma

• DOI: 10.1038/s41417-018-0070-x
• Publication Date: 2019-01-07T22:46:48Z
• Authors: Weilong Zhang; Ye Zhang; Zuozhen Yang; Xiaoni Liu; Ping Yang; Jing Wang; Kai Hu; Xue He; Xiuru Zhang; Hongmei Jing
• Keywords: Ubiquitin-conjugating enzyme

Multiple myeloma (MM) is one of hematological malignancies, characterized by malignant proliferation plasma cells. Biomarkers play an important role in evaluating the development and prognosis MM. Ubiquitin-conjugating enzyme E2T (UBE2T) served to connect with particular E3 ubiquitin ligase degraded-related substrates, contributing DNA repair Fanconi anemia pathway. Also, numerous evidences reported that UBE2T closely related cell carcinogenesis. However, relationship between MM has not been studied. Here, we integrated eight datasets analyzed expression ISS, 1q21, relapse survival 2684 patients (totally 2893 samples). We found increased deterioration (P = 1.4e-07), especially early stage. IgG serotype 6.9e-05). High associated poor (EFS: P 1.43e-03, OS: 5.47e-05). likely a part division pathway, affecting Therefore, could be considered as alternative biomarker for